Colorectal Cancer - Pipeline Review, H1 2020

June 2020 | 3889 pages | ID: C7AA7D24294EN
Global Markets Direct

Abstracts

Colorectal Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H1 2020, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 30, 217, 239, 1, 16, 290, 56 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 24, 11, 1, 37 and 4 molecules, respectively.
Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Colorectal Cancer - Overview
Colorectal Cancer - Therapeutics Development
Colorectal Cancer - Therapeutics Assessment
Colorectal Cancer - Companies Involved in Therapeutics Development
Colorectal Cancer - Drug Profiles
Colorectal Cancer - Dormant Projects
Colorectal Cancer - Discontinued Products
Colorectal Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Colorectal Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Colorectal Cancer - Pipeline by 3SBio Inc, H1 2020
Colorectal Cancer - Pipeline by 4D Pharma Plc, H1 2020
Colorectal Cancer - Pipeline by 4SC AG, H1 2020
Colorectal Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Colorectal Cancer - Pipeline by A2 Biotherapeutics Inc, H1 2020
Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
Colorectal Cancer - Pipeline by AB Science SA, H1 2020
Colorectal Cancer - Pipeline by AbbVie Inc, H1 2020
Colorectal Cancer - Pipeline by AbClon Inc, H1 2020
Colorectal Cancer - Pipeline by Abcuro Inc, H1 2020
Colorectal Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
Colorectal Cancer - Pipeline by Abpro Corp, H1 2020
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H1 2020
Colorectal Cancer - Pipeline by Acrotech Biopharma LLC, H1 2020
Colorectal Cancer - Pipeline by Adamed Sp zoo, H1 2020
Colorectal Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Colorectal Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Colorectal Cancer - Pipeline by ADT Pharmaceuticals Inc, H1 2020
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H1 2020
Colorectal Cancer - Pipeline by Advanced BioDesign, H1 2020
Colorectal Cancer - Pipeline by Advaxis Inc, H1 2020
Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Colorectal Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
4D Pharma Plc
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
A2 Biotherapeutics Inc
Aadi Bioscience Inc
AB Science SA
AbbVie Inc
AbClon Inc
Abcuro Inc
ABM Therapeutics Inc
Abpro Corp
Aclaris Therapeutics Inc
Acrotech Biopharma LLC
Adamed Sp zoo
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
ADT Pharmaceuticals Inc
Aduro BioTech Inc
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Affimed GmbH
Agency for Science, Technology and Research
Agenus Inc
Agilvax Inc
AIM ImmunoTech Inc
Akeso Inc
Alfasigma SpA
Alkermes Plc
Alligator Bioscience AB
Allinky Biopharma SL
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
AlphaMab Co Ltd
Alphamab Oncology
Alpine Immune Sciences Inc
Altimmune Inc
AltruBio Inc
ALX Oncology Inc
Amal Therapeutics SA
Amarin Corp Plc
amcure GmbH
Amgen Inc
AmMax Bio Inc
Ampo Biotechnology Inc
Amrita Therapeutics
Andes Biotechnologies
Anew Oncology Inc
Angex Pharmaceutical Inc
AnHeart Therapeutics Inc
Anwita Biosciences Inc
Apcegen Technologies Pvt Ltd
APEIRON Biologics AG
Apexian Pharmaceuticals Inc
Aphios Corp
Apogenix AG
Apollomics Inc
Apotex Inc
Aprogen Inc
Apros Therapeutics Inc
Araxes Pharma LLC
Arcus Biosciences Inc
Argonaut Therapeutics Ltd
AriBio
Arisaph Pharmaceuticals Inc
Arvinas Inc
Asana BioSciences LLC
Ascelia Pharma AB
Ascendis Pharma A/S
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Asclepiumm Taiwan Co Ltd
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atreca Inc
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
B Cell Design SAS
Bantam Pharmaceutical LLC
Barricade Therapeutics Corp
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing BGI-GBI Biotech Co Ltd
Beijing Biostar Technologies Ltd
Beijing Eastern Biotech Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Benhealth Biopharmaceutical (Shenzhen) Co Ltd
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla LLC
BIOCND Inc
Biocon Ltd
BioCurity Pharmaceuticals Inc
BioEclipse Therapeutics Inc
BioIntegrator Ltd
BioLineRx Ltd
BioMed Valley Discoveries Inc
BiomX Inc
Bionomics Ltd
BioNTech SE
Biosceptre International Ltd
BioXcel Therapeutics Inc
BioXpress Therapeutics SA
bluebird bio Inc
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Boston Biomedical Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4X Discovery Holdings Plc
Calithera Biosciences Inc
CanBas Co Ltd
Cancer Advances Inc
Cancer Prevention Pharmaceuticals Inc
Cancer Therapeutics Laboratories Inc
Canget BioTekpharma LLC
Cantargia AB
Cardiff Oncology Inc
Carna Biosciences Inc
CaroGen Corp
Carrick Therapeutics UK Ltd
CAS-Lamvac Biotech Co Ltd
CCRP Therapeutics GmbH
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellivery Therapeutics Inc
Cellix Bio Pvt Ltd
Cello Therapeutics Inc
Celltrion Inc
Celyad Oncology
Centus Biotherapeutics Ltd
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
ChemoCentryx Inc
Chengdu Huachuang Biotechnology Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chi Cheung (Shanghai) Biomedical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
ChoDang Pharm Co Ltd
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
Cinnagen Co
Cipla BioTec Pvt Ltd
Cleveland BioLabs Inc
Cloaked Therapeutics LLC
COARE Biotechnology Inc
Coherent Biopharma
Compass Therapeutics LLC
Compugen Ltd
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Curamir Therapeutics Inc
Curegenix Inc
Cynvec LLC
Cytlimic Inc
Cytodyn Inc
CytoMed Therapeutics Pte Ltd
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Decoy Biosystems Inc
Delta-Fly Pharma Inc
DevaCell Inc
Dicerna Pharmaceuticals Inc
Domain Therapeutics SA
Domainex Ltd
Dr. Reddy's Laboratories Ltd
Dragonboat Biopharmaceutical (Shanghai)Co Ltd
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Elicio Therapeutics
EnGeneIC Ltd
Enochian Biosciences Inc
EntreChem SL
Enzene Biosciences Ltd
Enzo Biochem Inc
EpicentRx Inc
Epygen Biotech Pvt Ltd
Esperas Pharma Inc
Eternity Bioscience Inc
Etubics Corp
Euclises Pharmaceuticals Inc
Evelo Biosciences Inc
Evotec SE
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
FivePhusion Pty Ltd
Fog Pharmaceuticals Inc
Formosa Pharmaceuticals Inc